Avalglucosidase Alfa Extension Study
Public ClinicalTrials.gov record NCT02032524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety and Pharmacokinetics of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) in Patients With Pompe Disease
Study identification
- NCT ID
- NCT02032524
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 19 participants
Conditions and interventions
Interventions
- Avalglucosidase Alfa Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2014
- Primary completion
- Dec 11, 2022
- Completion
- Dec 11, 2022
- Last update posted
- Feb 29, 2024
2014 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840006 | Phoenix | Arizona | 85013 | — |
| Investigational Site Number 840010 | Jacksonville | Florida | 32209 | — |
| Investigational Site Number 840001 | Kansas City | Kansas | 66160-7321 | — |
| Investigational Site Number 840008 | St Louis | Missouri | 63110 | — |
| Investigational Site Number 840002 | Durham | North Carolina | 27710 | — |
| Investigational Site Number 840011 | Cincinnati | Ohio | 45219 | — |
| Investigational Site Number 840009 | Dallas | Texas | 75390 | — |
| Investigational Site Number 840003 | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02032524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 29, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02032524 live on ClinicalTrials.gov.